ClinicalTrials.gg
CompletedNCT04092712Updated Sep 25, 2019

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

A Phase 1 interventional study of [14C]-CTP-543 in Healthy Volunteers, sponsored by Concert Pharmaceuticals. Completed at 1 site in United States. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-25.

Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2019, 7 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
19 Years to 55 Years
Sex
Male
01

Study summary

This study will assess the absorption, metabolism, excretion, mass balance, safety, and tolerability of a single oral administration of [14C]-CTP-543 in healthy male subjects.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Mass Balance
  • Radiolabeled
  • Pharmacokinetics
03

In context

Lead sponsor

Concert Pharmaceuticals is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.

First submitted before Concert Pharmaceuticals became part of Sun Pharmaceutical Industries Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects between the ages of 19 and 55 years, inclusive (healthy is determined by medical evaluation, including medical history, full physical examination, vital signs, , and clinical laboratory tests)
  • of 18.0 to 32.0 kg/m2
  • Continuous non smoker who has not used nicotine containing products for at least 3 months prior to dosing and throughout the study

Exclusion criteria

Exclusion Criteria:

  • Known immunodeficiency disorder, including positive serology for (HIV) at screening
  • Infection with or viruses
  • History of irregular bowel movements
  • History of herpes zoster
  • A positive tuberculosis test at screening or history of incompletely treated or untreated tuberculosis
  • History or presence of alcoholism or drug abuse within the past 2 years prior to dosing
  • Participation in another clinical study within 30 days prior to dosing
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Investigational Product

    \[14C\]-CTP-543

    Drug: [14C]-CTP-543

Interventions

  • Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution

06

What researchers measure

Primary outcomes

  1. Mass balance: Calculation of percent of total radioactivity recovered in urine

    Time frame: From time zero up to 96 hours post-dose following oral administration of [14C]-CTP-543 up to Day 15

  2. Mass balance: Calculation of percent of total radioactivity recovered in feces

    Time frame: From time zero up to 96 hours post-dose following oral administration of [14C]-CTP-543 up to Day 15

  3. CTP-543 PK: Cmax

    Maximum plasma concentration

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  4. CTP-543 PK: Tmax

    Time for Cmax

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  5. CTP-543 PK: t1/2

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  6. CTP-543 PK: AUClast

    Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration (Clast)

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  7. CTP-543 PK: AUCinf

    Area under the plasma concentration time profile from time 0 to infinity

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  8. CTP-543 PK: CL/F

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes).

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  9. CTP-543 PK: Vz/F

    Apparent volume of distribution following oral administration

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  10. CTP-543 metabolite PK: Cmax

    Maximum plasma concentration

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  11. CTP-543 metabolite PK: Tmax

    Time for Cmax

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  12. CTP-543 metabolite PK: t1/2

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  13. CTP-543 metabolite PK: AUC0-last

    Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration (Clast)

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  14. CTP-543 metabolite PK: AUCinf

    Area under the plasma concentration time profile from time 0 to infinity

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

  15. Total [14C]: urine

    Total radioactivity excreted into the urine from time zero to the time of last measurable concentration following oral administration of \[14C\]-CTP-543

    Time frame: Pre-dose up to 336 hours post-dose

  16. Total [14C]: feces

    Total radioactivity excreted into the feces from time zero to the time of last measurable concentration following oral administration of \[14C\]-CTP-543

    Time frame: Pre-dose up to 336 hours post-dose

  17. Total radioactivity in whole blood

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose

  18. Total radioactivity in plasma

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose

Secondary outcomes

  1. Adverse events

    Number of adverse events, which are any untoward medical occurrence regardless of attribution to study drug in a participant who received study drug

    Time frame: Screening up to Day 15

  2. Number of Participants With Clinically Significant Change From Baseline in Heart Rate

    Heart rate measured in beats per minute (bpm)

    Time frame: Screening, Pre-dose, 2, 8, 48 hours post-dose

  3. Number of Participants With Clinically Significant Change From Baseline in Blood Pressure

    Blood pressure measured in millimeters of mercury (mmHg)

    Time frame: Screening, Pre-dose, 2, 8, 48 hours post-dose

  4. Number of Participants With Clinically Significant Change From Baseline in Respiratory Rate

    Respiratory rate measured in breaths per minute

    Time frame: Screening, Pre-dose, 2, 8, 48 hours post-dose

  5. Number of Participants With Clinically Significant Change From Baseline in Temperature

    Temperature measured in Celsius (°C)

    Time frame: Screening, Pre-dose, 2, 8, 48 hours post-dose

  6. Number of Participants With Clinically Significant Change From Baseline in Hematology

    Time frame: Screening, Check-in, 8, 24 hours postdose

  7. Number of Participants With Clinically Significant Change From Baseline in Serum Chemistry

    Time frame: Screening, Check-in, 8, 24 hours postdose

  8. Number of Participants With Clinically Significant Change From Baseline in Coagulation

    Time frame: Screening, Check-in, 8, 24 hours postdose

  9. Number of Participants With Clinically Significant Change From Baseline in Urinalysis

    Time frame: Screening, Check-in, 8, 24 hours postdose

  10. Number of Participants With Clinically Significant Changes to the Physical Examination

    Clinically significant changes to the physical examination

    Time frame: Screening up to Day 15

  11. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - P Wave

    Time frame: Screening, Pre-dose, 48 hours post-dose

  12. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - QRS Complex

    Time frame: Screening, Pre-dose, 48 hours post-dose

  13. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - QT Interval

    Time frame: Screening, Pre-dose, 48 hours post-dose

07

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Sep 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2019
First posted
Sep 17, 2019
StartActual
Sep 5, 2019
Primary completionActual
Sep 11, 2019
CompletionActual
Sep 20, 2019
Last update
Sep 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04092712
Collaborators
Celerion
Responsible party
Sponsor
First posted
Sep 17, 2019
Start date
Sep 5, 2019
Primary completion
Sep 11, 2019
Completion
Sep 20, 2019
Last update
Sep 25, 2019

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion